Comparative Pharmacology
Head-to-head clinical analysis: BENDECTIN versus MECLODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDECTIN versus MECLODIUM.
BENDECTIN vs MECLODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of doxylamine (antihistamine) and pyridoxine (vitamin B6). Doxylamine blocks histamine H1 receptors, reducing nausea and vomiting. Pyridoxine acts as a cofactor in neurotransmitter synthesis, modulating nausea pathways.
Meclodium is a synthetic flavonoid derivative with antioxidant and anti-inflammatory properties. It inhibits lipid peroxidation and scavenges free radicals, protecting cell membranes from oxidative damage. It also modulates immune responses by reducing pro-inflammatory cytokine production.
10 mg doxylamine succinate + 10 mg pyridoxine hydrochloride orally once daily at bedtime, increased to twice daily (one tablet in morning and one at bedtime) and then three times daily (one tablet in morning, one in midafternoon, and one at bedtime) as needed, max 4 tablets per day.
Not a recognized drug.
None Documented
None Documented
Doxylamine: 10-12 hours (range 6-15h) in healthy adults; prolonged in hepatic impairment or elderly. Pyridoxine: 15-20 days (as pyridoxal phosphate in tissues); elimination half-life of pyridoxine per se is 2-3 hours.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal: mostly as metabolites. Doxylamine: ~60% as unchanged drug and metabolites; pyridoxine: ~70-80% as metabolites (primarily 4-pyridoxic acid). Fecal: minimal (<10%) for both components.
Renal: 70% unchanged; Biliary/fecal: 20% as metabolites; 10% minor pathways.
Category C
Category C
Antiemetic
Antiemetic